OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Psychopharmacology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	218
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA)	144
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	133
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	103
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	74
Award winning abstracts presented at the 15 ^th Annual International College of Mental Health Pharmacy (CMHP) Conference, Liverpool, UK, on 10	60
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	59
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	58
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	56
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	54
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	53
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	53
Neurocognitive changes in lithium-treated older adult bipolar patients on antipsychotics	53
Psychedelics and the ‘inner healer’: Myth or mechanism?	52
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	51
Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression	50
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	47
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	47
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	42
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	42
The effects of antenatal depression and SSRI exposure on children: A systematic review	40
Dynamic excitatory-inhibitory differences in autistic and non-autistic adults: Evidence from a pharmacological challenge with arbaclofen	39
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	39
Psychedelic research – Going global	37
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	37

Comparison of average time-to-relapse following ECT versus ketamine – A systematic review	36
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	33
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	33
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	33
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	32
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	31
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	31
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs	31
Not too quick on “Debunking the myth of ‘Blue Mondays’”	30
Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data	30
Every prescription is a prediction	28
What are set and setting: Reducing vagueness to improve research and clinical practice	28
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust	28
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	27
The therapeutic readiness of probiotics in major depressive disorder: A systematic review of randomised controlled trials	27
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis	26
The renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers	26
Ten practical suggestions for setting up a psychedelic study	25
The New Zealand drug harms ranking study: A multi-criteria decision analysis	24
The goal of specificity in psychotropic drug development: A lesson from Sisyphus?	23
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19 / CYP2D6 genes play a	23
Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature	23
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder	23
Antipsychotic co-medication and treatment response to rTMS and iTBS in depression: Data from clinical records from two independent clinical sites	21
Psychedelic-assisted psychotherapy: The need to monitor adverse events	21
Cardiovascular mortality and depression: A systematic review and meta-analysis of the association with antidepressant treatment and co-morbidity	21
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α ₂ -adrenoceptor	21
The low risk for early renal damage during lithium treatment has not changed over time	21
The mechanism of action of clozapine	20
Statistical limitations of the claimed dose–response in “Dose–response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials”	20
Impact of psychedelics on craving in addiction: A systematic review	20
Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder	20
Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review	19
The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences	19
Oxytocin prevents ketamine-induced executive control deficits in macaque monkeys	19
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)	19
Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants	18
Drug–drug interactions involving classic psychedelics: A systematic review	18
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program	18
Genetic background and sex moderate the effects of adolescent nicotine exposure on adult functional neural circuits and behavior	18
Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys	17
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced	17
Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR ₉ ) measure of suicidal risk	17
Effect of CannEpil ^® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial	17
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospec	17
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample	17
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia	16
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study	16
Eight-week antidepressant treatment effects on connectome gradient in first-episode drug-naïve patients with major depressive disorder	16

Psilocybin for clinical indications: A scoping review	16
The effects of reserpine on depression: A systematic review	15
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression	15
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression	15
The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential	15
Factor analysis of treatment acceptability in double-blind randomised clinical trial of home-based transcranial direct current stimulation in major depression and in healthy individuals	15
The increasing use of cognitive enhancing drugs by those with ADHD and neurotypical individuals: Societal demands, lifestyle preferences, and ethical issues	14
Assessment of the reporting of harms in systematic reviews focused on hallucinogens: A cross-sectional study	14
The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database	14
Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing	14
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	14
Escitalopram and functional connectivity in major depressive disorder: A systematic review	14
A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions	14
Negative affect interacts with perceptual affective biases	14
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?	13
Exploring the efficacy and safety of a novel standardized ashwagandha ( Withania somnifera ) root extract (Witholytin®) in adults experiencing high stres	13
Blackcurrant ( Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice	13
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research	13
Modafinil: A closer look at its theoretical toxicological potential	13
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior	13
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	12
Risk of major congenital malformations and heart defects in pregnancies exposed to first-trimester drugs for depression and co-medications	12
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review	12
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	12
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	12
Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review	12
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder	12
Older adults in psychedelic-assisted therapy trials: A systematic review	12
Episodic foresight is impaired following acute alcohol intoxication	12
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial	12
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	12
Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 5	12
Subjectively reported sleep improvement with antipsychotic medications in clinical practice: A systematic review, meta-analysis and meta-regression of moderating factors	12
The role of psychopharmacology and cognitive neuroscience in understanding the brain in the treatment of psychiatric disorders and neurological diseases for the benefit of society	11
Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression	11
No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study	11
Recasting the role of electroconvulsive therapy and the electroconvulsive therapy practitioner: For severe illness, not necessarily treatment-resistant depression	11
Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour	11
Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience	11
Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis	11
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	11
The association between N -methyl- d -aspartate receptor availability and glutamate levels: A multi-mo	11
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy vo	11
A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects	11
The psychedelic effects of cannabis: A review of the literature	11
Common protein networks for various drug regimens of major depression are associated with complement and immunity	11
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	11
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments	10
Sub-anesthetic doses of ketamine increase single cell entrainment in the rat auditory cortex during auditory steady-state response	10
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	10
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study	10
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations	10
Concomitant use of antidepressants and classic psychedelics: A scoping review	10
Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights	10
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects	9
Role of chemokines in depression: Highlights on CX ₃ CL1/CX ₃ CR1 signaling	9
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database	9
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	9
No evidence that post-training dopamine D2 receptor agonism affects fear generalization in male rats	9
The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression	9
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records	9
Interactions of alcohol and the benzodiazepine inverse agonist in healthy male volunteers	8
Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference?	8
Mediators of treatment response in a clinical trial of naltrexone and bupropion for methamphetamine use disorder: A longitudinal mediation analysis	8
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain	8
Trip killers: Addressing a critical knowledge gap in psychedelic research	8
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study	8
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature	8
Landscape analysis of pre-registered clinical trials involving classical psychedelics	8
Prenatal THC exposure and binge-like alcohol drinking in early adolescence: From sex-specific drinking vulnerability to abnormal endocannabinoid-dopamine nexus in the nucleus accumbens	8
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms	8
Role of serotonin in modulation of decision-making in Parkinson’s disease	8
Clinical correlates of early onset antipsychotic treatment resistance	8
Ketamine: A new chapter for clinical psychopharmacology?	8
Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights	8
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I	8
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	8
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	8